157 related articles for article (PubMed ID: 28503810)
41. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
[TBL] [Abstract][Full Text] [Related]
42. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
43. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models.
Al-Aridi C; Abboud MR; Saab R; Eid D; Jeha S; Chan AK; Muwakkit SA
Pediatr Hematol Oncol; 2011 Nov; 28(8):676-81. PubMed ID: 21787123
[TBL] [Abstract][Full Text] [Related]
44. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
45.
Mootoosamy C; Kondyli M; Serfaty SA; Tremblay DÉ; Gagné V; Ribère M; Laverdière C; Leclerc JM; Sinnett D; Tran TH; Krajinovic M
Pharmacogenomics; 2023 Mar; 24(4):199-206. PubMed ID: 36946317
[TBL] [Abstract][Full Text] [Related]
46. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
Abbott LS; Deevska M; Fernandez CV; Dix D; Price VE; Wang H; Parker L; Yhap M; Fitzgerald C; Barnard DR; Berman JN
Blood; 2009 Dec; 114(25):5146-51. PubMed ID: 19822902
[TBL] [Abstract][Full Text] [Related]
47. Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Chen SH
Pediatr Neonatol; 2015 Oct; 56(5):287-93. PubMed ID: 25603726
[TBL] [Abstract][Full Text] [Related]
48. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.
Liu WJ; Wang H; Wang WD; Zhu MY; Liu CC; Wang JH; Lu Y
Sci Rep; 2016 Dec; 6():39463. PubMed ID: 28000713
[TBL] [Abstract][Full Text] [Related]
49. L-asparaginase induced intracranial haemorrhage in acute lymphoblastic leukemia.
Lim HL; Teo CP; Wong K; Kueh YK
Singapore Med J; 1998 Feb; 39(2):76-8. PubMed ID: 9652181
[TBL] [Abstract][Full Text] [Related]
50. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
51. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
52. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
[TBL] [Abstract][Full Text] [Related]
53. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
George G; Rezazadeh A; Zook F; Pearl N; McCoy C; Carlson K; Runaas L; Abedin S; Guru Murthy GS; Michaelis LC; Atallah E; Baumann-Kreuziger L
Leuk Res; 2020 Jul; 94():106368. PubMed ID: 32442786
[No Abstract] [Full Text] [Related]
54. Treatment-induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to consider.
El-Khoury H; Saifi O; Haddad S; Chahrour M; Ghanem KM; Mubarak Y; Tamim H; Makki M; Zakka C; Chan AK; Mahfouz R; Tarek N; El-Solh H; Abboud MR; Saab R; Muwakkit SA
Pediatr Blood Cancer; 2021 Nov; 68(11):e29210. PubMed ID: 34327817
[TBL] [Abstract][Full Text] [Related]
55. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience.
Ruiz-Delgado GJ; Macías-Gallardo J; Lutz-Presno JA; Montes-Montiel M; Ruiz-Argüelles GJ
Leuk Lymphoma; 2011 Feb; 52(2):314-6. PubMed ID: 21054153
[No Abstract] [Full Text] [Related]
56. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
57. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
[TBL] [Abstract][Full Text] [Related]
58. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
59. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Rank CU; Wolthers BO; Grell K; Albertsen BK; Frandsen TL; Overgaard UM; Toft N; Nielsen OJ; Wehner PS; Harila-Saari A; Heyman MM; Malmros J; Abrahamsson J; Norén-Nyström U; Tomaszewska-Toporska B; Lund B; Jarvis KB; Quist-Paulsen P; Vaitkevičienė GE; Griškevičius L; Taskinen M; Wartiovaara-Kautto U; Lepik K; Punab M; Jónsson ÓG; Schmiegelow K
J Clin Oncol; 2020 Jan; 38(2):145-154. PubMed ID: 31770057
[TBL] [Abstract][Full Text] [Related]
60. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
